List of works - Christian Klein

A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors ⬇️

scientific article published on February 6, 2013

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells

scientific article published on 28 November 2016

A modular and controllable T cell therapy platform for acute myeloid leukemia

scientific article published on 07 January 2021

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

scientific article published on 11 June 2018

Anti-CD20 treatment for B-cell malignancies: current status and future directions

scientific article published on 15 September 2020

Antibodies against CD20 or B-Cell Receptor Induce Similar Transcription Patterns in Human Lymphoma Cell Lines ⬇️

scientific article (publication date: 18 February 2011)

Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab

scientific article published on 23 September 2019

Bispecific Antibody Derivatives Based on Full-Length IgG Formats ⬇️

scientific article published on 01 January 2012

Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma

scientific article published on 17 December 2018

CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins

scientific article published on 01 January 2020

CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies

scientific article published on 01 May 2018

Calcium channel blockers impair the antitumor activity of anti-CD20 monoclonal antibodies by blocking EGR-1 induction

scientific article published on 26 August 2020

Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma.

scientific article published on 15 September 2017

Combination therapy with the type II anti-CD20 antibody obinutuzumab.

scientific article published on 26 August 2017

Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells

scientific article published on 17 April 2019

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

scientific article published on 01 March 2020

Development of tetravalent IgG1 dual targeting IGF-1R–EGFR antibodies with potent tumor inhibition ⬇️

scientific article published on March 21, 2012

DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity

scientific article published on 17 September 2019

Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties ⬇️

scientific article published on August 29, 2012

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells

scientific article published in 2022

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101 ⬇️

scientific article published on January 1, 2011

Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy

scientific article published on 03 May 2019

Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer

scientific article published on 03 November 2020

Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody

scientific article published on 24 June 2020

The PET-tracer 89Zr-Df-IAB22M2C enables monitoring of intratumoral CD8 T cell infiltrates in tumor-bearing humanized mice after T cell bispecific antibody treatment

scientific article published on 14 May 2020

The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.

scientific article published on 16 February 2018

The physiological interactome of TCR-like antibody therapeutics in human tissues

scientific article published in 2024

Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia